Anlotinib Retrospective Study for Esophageal Cancer
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.
Esophageal Neoplasms
DRUG: Anlotinib
PFS, Progression Free Survival, From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
OS, Overall Survival, From date of admission until the date of death from any cause, assessed up to 24 months
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.